Muscle Mass During Space Exploration
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00968344|
Recruitment Status : Completed
First Posted : August 31, 2009
Results First Posted : May 31, 2019
Last Update Posted : May 31, 2019
The investigators will test the following hypotheses:
- Bedrest will blunt the anabolic response to a mixed nutrient meal, facilitating a loss of muscle mass and functional capacity that is only partially restored during rehabilitation.
- Enriching daily meals with leucine will promote protein synthesis and maintain the anabolic response to mixed nutrient meal ingestion. This will preserve lean muscle mass and function during bedrest and facilitate the recovery of functional and metabolic capacity during rehabilitation.
|Condition or disease||Intervention/treatment||Phase|
|Muscle Loss||Dietary Supplement: Leucine Dietary Supplement: Alanine||Not Applicable|
Our long-term goal is to identify, prevent and remedy defects in the metabolic pathway that contribute to the loss of muscle mass and function during exposure to microgravity. Demographic data indicate that the average age of shuttle crew members has increased from 40.7 yrs in 1995 to 46.7 yrs in 2007 with an increasing number of astronauts over 50 yrs of age. We contend that the loss of muscle mass and function during spaceflight is facilitated by an age-associated, progressive impairment in the ability to mount an anabolic response to standard mixed nutrient meals. We propose that enriching daily meals with a low-volume leucine supplement will reduce the deleterious effects of microgravity on skeletal muscle and facilitate recovery during rehabilitation.
We will employ our established 14 day bed rest protocol to model the skeletal muscle unloading that occurs during microgravity. We will also examine recovery of muscle mass and functional capacity during a 7 day rehabilitation period. We will study 2 groups: CON (Bedrest/Recovery + Placebo; n=15), LEU (Bedrest/Recovery + Leucine; n=15). We will assess a) markers of translation initiation, b) muscle protein synthesis, c) muscle mass and body composition and d) strength and aerobic capacity.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||40 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Intervention: leucine|
|Masking:||Double (Participant, Investigator)|
|Primary Purpose:||Basic Science|
|Official Title:||An Integrated Low-Volume Nutritional Countermeasure to Maintain Muscle Mass and Function During Space Exploration|
|Study Start Date :||August 2009|
|Actual Primary Completion Date :||April 2015|
|Actual Study Completion Date :||April 2015|
3-4 g Leucine added to daily meals during bed rest
Dietary Supplement: Leucine
3-4g Leucine added to daily meals
Placebo Comparator: Placebo
3-4 g Alanine added to daily meals during bed rest
Dietary Supplement: Alanine
Powered amino acid
- Lean Leg Mass [ Time Frame: At baseline prior to beginning bed rest and after 14 days of bed rest ]DEXA scan of both legs pre/post bed rest
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00968344
|United States, Texas|
|The University of Texas Medical Branch|
|Galveston, Texas, United States, 77555|
|Principal Investigator:||Douglas Paddon-Jones, PhD||The University of Texas Medical Branch at Galveston|